BioSpace News Archive

Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report today that a Machine Learning (Artificial Intelligence) model used to screen 1,482 compounds ranked Brilacidin in the top three percent of compounds predicted to be the most effective against SARS-CoV-2

Sterigenics S.A.S., a subsidiary of Sotera Health and a global leader in comprehensive sterilization services, announces the expansion of its ethylene oxide (EO) facility located in Rantigny, France to increase European sterilization capacity

MJ Biotech, Inc., partner Genesis Botanical Research, is pleased to report they have broken ground on a second foundation which will be used to store hemp biomass.

Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced that management will participate in the 33rd Annual Roth Conference, which will be held on March 15-17, 2021.

Bright Minds Biosciences, a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain, announced that Ian McDonald, Chief Executive Officer, will be presenting at the Stifel GMP Healthcare Conference – Healthcare Psychedelics: Addressing the Global Mental Health Crisis

Satsuma Pharmaceuticals, Inc . (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that management will present a corporate overview at the 31 st Annual Oppenheimer Healthcare Conference on March 16, 2021 at 3:10 PM Eastern Time. The conference will be held virtually with participants joining remotely from March 16 th to the 18 th . A webcast of the presentation can be followed live online via the link

Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases currently treated with burdensome and painful injections, as evidenced by its recent approval of MYCAPSSA as the first and only oral therapy for the treatment of acromegaly

Oncology Pharma Inc. (OTC: ONPH): Today, the company announced it is putting together a short list of contract research organizations (CROs) to assist in developing a research plan, along with indications for treatment in developing intellectual property towards commercialization.

Total Company Net Revenue Increased 40% versus Prior Year to Reach an All-Time High of $156.5 Million Record Level Profitability with Net Income of $25.7 Million, Full-Year EBITDA Margin of 26% and Operating Cash Generation of $25 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today

GT Biopharma, Inc.today announced that management will present at the Virtual 33rd Annual Roth Conference on Wednesday, March 17th, 2021 at 12:00 p.m. ET (9:00am PT).